Janssen to use Vectura's inhaler tech for COPD, asthma

Vectura Group plc (LSE:VEC) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) an exclusive, worldwide license to use its dry power inhaler technology to develop anti-inflammatory therapies for asthma and chronic obstructive pulmonary disease (COPD).

The companies did not disclose financial details, but Vectura said the deal comprises an upfront payment plus development milestones and tiered royalties. ...